http://www.amarantus.com/

Shares Outstanding 81,016,330 a/o Nov 14, 2011
http://www.otcmarkets.com/stock/AMBS/news
http://www.otcmarkets.com/stock/AMBS/financials
Management Team

Gerald E. Commissiong

President & CEO
Mr. Commissiong was appointed President & CEO of Amarantus BioSciences in October 2011. In March 2011, Mr. Commissiong was

promoted to Chief Operating Officer of Amarantus, where his duties included strategic transactions, licensing, research

collaborations, mergers & acquisitions, fund raising and investor relations. From August 2009 until March 2011, he served as

Chief Business Officer where he was responsible for business development and corporate development. In 2008, Mr. Commissiong

co-founded Amarantus with Dr. John Commissiong PhD and served as its President & CEO until August 2009. In that timeframe,

Mr. Commissiong attracted seed capital, acquired the intellectual property rights to MANF and recruited scientific and

executive talent to Amarantus to allow for the further development of the technologies. Mr. Commissiong has served as a

Director of Amarantus since 2008. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the

Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering

with a focus Financial Decisions from Stanford University.

John W. Commissiong, PhD

Chief Scientific Officer
Dr. Commissiong has served as the Chief Scientific Officer and a Director of Amarantus since co-founding the company in 2009.

From 2000 through 2008 Dr. Commissiong served as the CSO of Neurotrophics Inc & Prescient Neuropharma Inc. Dr. Commissiong

has been focused on the discovery of novel neurotrophic factors for the treatment of neurodegenerative diseases as well as

understanding the fundamental underlying biology of protoplasmic type-1 astrocytes that secrete neurotrophic factors. He was

Chief of the Neural Transplantation Unit, NINDS-NIH, from 1989-94 where his research focused on identifying therapeutic

approaches to spinal cord injury. Dr. Commissiong was Head of the Neurotrophic Factors Group, NINDS-NIH, from 1994-97 where

he focused on developing technologies to systematically identify novel neurotrophic factors with applications for specific

Central Nervous System disorders. He co-founded Prescient Neuropharma in 1999, and discovered MANF in 2003. MANF is currently

in preclinical development for the treatment of Parkinson’s disease. The work pioneered by Dr. Commissiong has led to

significant advancements in the field of astrocyte-neuron biology. Dr. Commissiong believes that a fundamental understanding

of astrocyte-neuron interactions in the Central Nervous System will lead to a new generation of therapies to treat brain-

related disorders.
Dr. Commissiong did his Postdoctoral work in the Lab Preclin Pharmac, NIMH-NIH, concentrating on the application of

quadrupole mass spectrometry in the analysis of neurotransmitters. He holds a Ph.D. in Neurophysiology from the University of

Southampton, an M.Sc. in Biochemical Pharmacology from the University of Southampton, and a B.S. in Biology and Chemistry

from the University of the West Indies.

Marc E. Faerber

Controller / Chief Financial Officer Controller
Mr. Faerber has over thirty years of experience and over nineteen of those in life sciences. His experience has spanned

Fortune 500 companies to start-ups, and everything in between. During the past ten years Mr. Faerber has been providing

financial, business and advisory services to a broad base of start-up companies primarily in the fields of cardiology,

gastroenterology, orthopedics, diagnostics and biotechnology.
Mr. Faerber has extensive transactional experience, including considerable experience in establishing international

organizations throughout Europe and parts of Asia, international technology licensing and distribution transactions, mergers

and acquisitions, and numerous funding transactions, including an initial public offering as well as other international

business structural issues. During Mr. Faerber’s career he has held various positions in finance and corporate management

including CFO, CEO and Director. Mr. Faerber started his career working for KPMG, is a certified public accountant, and has a

Bachelor of Sciences in Business Administration from Providence College.